Analyses of surface antigens on donor-derived cells in MRL/lpr mice treated with 5.5 Gy × 2 + IBM
| Mice‡ . | Cell surface antigen (%)† . | ||||
|---|---|---|---|---|---|
| B220 . | CD4 . | CD8 . | CD11b . | Gr-1 . | |
| MRL/lpr mice treated with | |||||
| 5.5 Gy × 2 + IBM | |||||
| Spleen cells | 18.5 ± 8.9 | 3.7 ± 2.0 | 6.9 ± 2.4 | 40.2 ± 4.2 | 42.2 ± 3.5 |
| BMCs | 16.5 ± 4.6 | 1.9 ± 1.5 | 2.9 ± 1.2 | 55.3 ± 8.8 | 65.6 ± 3.9 |
| HMNCs | 18.0 ± 2.3 | 1.2 ± 0.2 | 19.1 ± 2.5 | 40.4 ± 8.6 | 46.5 ± 9.6 |
| 5.5 Gy × 2 + PV | |||||
| Spleen cells | 10.8 ± 6.3 | 1.0 ± 0.5 | 4.7 ± 1.1 | 36.3 ± 5.9 | 38.5 ± 2.0 |
| BMCs | 9.9 ± 3.9 | 0.5 ± 0.1 | 2.0 ± 0.7 | 48.9 ± 0.5 | 57.2 ± 5.2 |
| HMNCs | 10.3 ± 4.3 | 1.5 ± 0.3 | 5.5 ± 1.91-160 | 42.2 ± 2.8 | 48.5 ± 5.8 |
| 5.5 Gy × 2 + IV | |||||
| Spleen cells | 0.4 ± 0.5* | 0.2 ± 0.2 | 0.5 ± 0.5* | 3.8 ± 2.31-160 | 4.3 ± 4.01-160 |
| BMCs | 2.7 ± 1.41-160 | 0.4 ± 0.2 | 1.1 ± 0.8 | 27.9 ± 8.6* | 26.0 ± 3.91-160 |
| HMNCs | 0.5 ± 0.41-160 | 0.4 ± 0.3* | 0.4 ± 0.41-160 | 9.6 ± 4.6* | 13.0 ± 11.0* |
| Normal B6 mice | |||||
| Spleen cells | 51.8 ± 6.7 | 18.3 ± 3.3 | 15.3 ± 3.3 | 6.6 ± 1.2 | 7.4 ± 1.0 |
| BMCs | 13.8 ± 0.3 | 1.5 ± 0.4 | 1.1 ± 0.1 | 48.0 ± 1.4 | 54.0 ± 13.2 |
| HMNCs | 36.9 ± 2.3 | 24.3 ± 0.3 | 7.5 ± 0.2 | 21.8 ± 1.8 | 20.6 ± 2.5 |
| Mice‡ . | Cell surface antigen (%)† . | ||||
|---|---|---|---|---|---|
| B220 . | CD4 . | CD8 . | CD11b . | Gr-1 . | |
| MRL/lpr mice treated with | |||||
| 5.5 Gy × 2 + IBM | |||||
| Spleen cells | 18.5 ± 8.9 | 3.7 ± 2.0 | 6.9 ± 2.4 | 40.2 ± 4.2 | 42.2 ± 3.5 |
| BMCs | 16.5 ± 4.6 | 1.9 ± 1.5 | 2.9 ± 1.2 | 55.3 ± 8.8 | 65.6 ± 3.9 |
| HMNCs | 18.0 ± 2.3 | 1.2 ± 0.2 | 19.1 ± 2.5 | 40.4 ± 8.6 | 46.5 ± 9.6 |
| 5.5 Gy × 2 + PV | |||||
| Spleen cells | 10.8 ± 6.3 | 1.0 ± 0.5 | 4.7 ± 1.1 | 36.3 ± 5.9 | 38.5 ± 2.0 |
| BMCs | 9.9 ± 3.9 | 0.5 ± 0.1 | 2.0 ± 0.7 | 48.9 ± 0.5 | 57.2 ± 5.2 |
| HMNCs | 10.3 ± 4.3 | 1.5 ± 0.3 | 5.5 ± 1.91-160 | 42.2 ± 2.8 | 48.5 ± 5.8 |
| 5.5 Gy × 2 + IV | |||||
| Spleen cells | 0.4 ± 0.5* | 0.2 ± 0.2 | 0.5 ± 0.5* | 3.8 ± 2.31-160 | 4.3 ± 4.01-160 |
| BMCs | 2.7 ± 1.41-160 | 0.4 ± 0.2 | 1.1 ± 0.8 | 27.9 ± 8.6* | 26.0 ± 3.91-160 |
| HMNCs | 0.5 ± 0.41-160 | 0.4 ± 0.3* | 0.4 ± 0.41-160 | 9.6 ± 4.6* | 13.0 ± 11.0* |
| Normal B6 mice | |||||
| Spleen cells | 51.8 ± 6.7 | 18.3 ± 3.3 | 15.3 ± 3.3 | 6.6 ± 1.2 | 7.4 ± 1.0 |
| BMCs | 13.8 ± 0.3 | 1.5 ± 0.4 | 1.1 ± 0.1 | 48.0 ± 1.4 | 54.0 ± 13.2 |
| HMNCs | 36.9 ± 2.3 | 24.3 ± 0.3 | 7.5 ± 0.2 | 21.8 ± 1.8 | 20.6 ± 2.5 |
Spleen cells, BMCs, and HMNCs in MRL/lpr mice 14 days after the treatment with 5.5 Gy × 2 + IBM, 5.5 Gy × 2 + PV, or 5.5 Gy × 2 + IV were stained with FITC-anti-H-2Db or PE-conjugated mAbs specific for mature lineage markers (listed in the table), and analyzed using a FACScan.
The results are expressed as the mean ± SD of 6 mice. Asterisks represent P values of 5.5 Gy × 2 + IBM versus 5.5 Gy × 2 + PV or 5.5 Gy × 2 + IV;
P < .01,
P < .001.